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Bacterial infection following cancer chemotherapy-induced neutropenia is a serious cause of
morbidity and mortality in human and veterinary patients. Antimicrobial prophylaxis is contro-
versial in the human oncology field, as any decreased incidence in bacterial infections is
countered by patient adverse effects and increased antimicrobial resistance. Comprehensive
guidelines exist to aid human oncologists in prescribing antimicrobial prophylaxis but similar
recommendations are not available in veterinary literature. As the veterinarian's role in antimi-
crobial stewardship is increasingly emphasized, it is vital that veterinary oncologists implement
appropriate antimicrobial use. By considering the available human and veterinary literature we
present an overview of current clinical practices and are able to suggest recommendations for
prophylactic antimicrobial use in veterinary cancer chemotherapy patients.
KEYWORDS
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1 | INTRODUCTION
The aim of antimicrobial prophylaxis is to administer antimicrobials to
patients considered to be at risk of infection in order to prevent an
infection from developing. Patients at risk of infection include those
undergoing surgical procedures or those with immunosuppression for
a variety of reasons including cancer chemotherapy. However, as
multi-resistant organisms continue to emerge and few new antimicro-
bials are approved, current antimicrobial use protocols have come
under intense scrutiny.1 This is particularly true in the veterinary
setting as evidence mounts on the possibility of transfer of resistant
organisms or genes not only between animals but also from animals to
humans.2
Antimicrobial stewardship among veterinary practitioners is key
in reducing the selection pressure for resistant bacteria3 with the
American Veterinary Medical Association urging vets to “commit to
stewardship.”4 The British Veterinary Association's 7-point plan for
the responsible use of antimicrobials goes a step further to specifically
advise minimizing prophylactic antimicrobial use.5 However, in order
to achieve this, effective guidelines on antimicrobial administration
are essential. For surgical prophylactic antimicrobial use, numerous
recommendations, based on veterinary and human literature, are now
available to guide clinicians.6,7 However, there is evidence from the
United Kingdom, Australia, New Zealand and Belgium that despite the
availability of antimicrobial usage guidelines there is still poor compli-
ance and suboptimal use of antimicrobials in both prophylactic and
disease settings.6,8–11 This poor compliance may be due in part to the
numerous and often slightly conflicting resources available and a sub-
sequent lack of clear message.
In the setting of veterinary cancer chemotherapy antimicrobial
prophylaxis is a newer concept, and far fewer resources are available
to guide clinicians.7,12,13 Any recommendations are often minimally
evidence based and may not be easy to access. At this stage, there is
an opportunity to create clear, unified and evidence-based guidelines
and potentially avoid the plethora of data sources and ingrained prac-
tice policies that can complicate surgical antimicrobial prophylaxis.
In human oncology there is ongoing debate surrounding prophy-
lactic antimicrobial use. This is due to fears of resistant organism
development and the reduction in efficacy of cancer chemotherapeu-
tics counteracting the benefits of infection prevention.14 One human
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literature review and modelling study suggested that for a 30% reduc-
tion in antimicrobial efficacy there would be 683 additional deaths per
year in patients receiving chemotherapy for haematological malignan-
cies.15 This suggests that some cancer chemotherapy patients have a
marked benefit from antimicrobial use, however, only if antimicrobials
are appropriate and efficacious. It is therefore vital that we try to
preserve antimicrobial efficacy for these at risk patients by using them
appropriately. By assessing evidence from both human and veterinary
literature, it is possible to determine whether veterinary patients
receiving cancer chemotherapy require prophylactic antimicrobials
and to outline defined criteria for their use.
2 | NEUTROPENIA
As neutrophils are a vital component of the innate immune response,
any depletion in neutrophil number can predispose the patient to
infection and provide an indication for antimicrobial prophylaxis.
Neutropenia following chemotherapy administration is a well-
characterized adverse event in both human and veterinary oncology.
Typical normal reference ranges for absolute neutrophil count (ANC)
in complete blood counts (CBCs) in dogs and humans are around
3 x 109 to 7 x 109/L, although this varies between laboratories.
Human studies in the 1960s identified an increased risk of infection
when the ANC fell below 2 x 109/L, with patients below 0.5 x 109/L
were considered to be high risk and below 0.2 x 109/L were very high
risk.16 More contemporary human studies define a neutropenia of
clinical concern as below 1.0 x 109/L with most centres focusing on
patients with an ANC of less than 0.5 x 109/L.17–19 In veterinary
patients, the Veterinary Cooperative Oncology Group has created a
grading system to allow classification of the various levels of neutro-
penia following chemotherapy administration. According to this
system an ANC of below 0.5 x 109/L is classified as a grade 4, severe
neutropenia.20 For veterinary patients, a grade 3 neutropenia
(<1 x 109/L) is generally considered clinically significant, particularly if
there is likely to be a decline in neutrophil numbers in the next 24 to
48 hours.12,21,22 Prevalence of grade 3 or 4 neutropenia in humans
varies widely from around 10% to over 40% dependant on the centre,
type of chemotherapy protocol used and any specific patient risk
factors.15,23 The prevalence in dogs is generally considered to be
lower than in humans but varies widely between studies and depends
on the chemotherapy protocol used.24–26
Of additional importance in conjunction with the ANC is the clini-
cal status of the patient. In particular, pyrexia accompanying a neutro-
penia is of far more clinical concern than if a patient is afebrile and
clinically well, as it indicates the probable presence of infection.
Febrile neutropenia is a medical emergency for both veterinary and
human patients, necessitating immediate medical attention and
administration of empirical broad spectrum antimicrobials to prevent
progression of infection.27 Human chemotherapy protocols are classi-
fied as high, intermediate or low risk for inducing febrile neutropenia,
with high-risk protocols resulting in a febrile neutropenia rate of
greater than 20%.28 Most current human protocols are classified as
intermediate risk with one recent retrospective cohort study in the
United States identifying a 16.8% rate of febrile neutropenia in
patients receiving chemotherapy for a solid tumour or non-Hodgkins
lymphoma.19,28 In this study, 83.2% of febrile neutropenic patients
were hospitalized and hospital mortality rate was 8.1%.19 The risk of
febrile neutropenia appears to be lower in veterinary patients, with
most studies reporting rates of less than 10%.21,26,29 However, higher
rates are reported with some chemotherapy protocols30,31 and
mortality among hospitalized canine patients is similar to the human
studies with rates around 8%.32
3 | HUMAN TRIALS ASSESSING
ANTIMICROBIAL USE
There are now several randomized control trials assessing prophylactic
antimicrobials in human cancer chemotherapy patients. Two large
trials assessed the efficacy of levofloxacin compared to a placebo
given prophylactically to patients receiving chemotherapy for various
malignancies. In these trials there was a statistically significant
reduction in fever, microbiologically documented infections and
hospitalization, although there was no significant difference in mortal-
ity between the two groups.18,33 Meta-analysis of multiple random-
ized control trials did indicate a reduction in mortality for neutropenic
patients on antimicrobial prophylaxis although some trials in these
analyses were inadequately powered to accurately predict
mortality.34,35
Even without strong evidence for a reduction in mortality with
antimicrobial prophylaxis in humans there is reasonable evidence in
humans for a reduction in febrile neutropenias and hospitalization
rates.36 This reduction has multiple positive outcomes including a
reduction in the cost of the overall treatment (an extremely important
factor for organizations such as the National Health Service [NHS]).
In addition, one human study found that patients with hospitalization
because of febrile neutropenia in their first chemotherapy cycle were
4.4 times more likely to terminate their chemotherapy protocol
prematurely than those who were not hospitalized.37
4 | VETERINARY LITERATURE
There are far fewer studies assessing the efficacy of antimicrobial
prophylaxis in dogs. One, much cited, double-blinded placebo-
controlled study assessed prophylactic trimethoprim sulfadiazine
(TMPS) administration during doxorubicin chemotherapy in dogs with
lymphoma and osteosarcoma. Seventy-three dogs were investigated,
34 with osteosarcoma and 39 with lymphoma. Dogs receiving prophy-
lactic TMPS experienced a significant reduction in non-hematologic
toxicity (gastrointestinal toxicity, hospitalization, suspected infection)
compared to the placebo group. However, the occurrence of sepsis
was not specifically assessed in this study and the chemotherapy
protocol was low risk with only 3 out of 73 animals developing febrile
neutropenia.24 Several other studies in dogs have used TMPS prophy-
laxis, particularly when investigating protocols with a higher dose
intensity and where more severe haematological toxicity was
expected.38–40 It is difficult to compare infection and hospitalization
rates between studies particularly as different protocols and hospital
2 BISSON ET AL.
populations are involved. In this context, some studies reported a
higher incidence of myelosuppression than with other more standard
protocols but no associated increase in hospitalization or febrile neu-
tropenia among the dogs, suggesting a possible protective role for
TMPS used in this setting.41,42
A few veterinary papers have conflicting evidence about the
efficacy of antimicrobial prophylaxis. One case series assessing the
toxicity associated with epirubicin in dogs found no difference in
the percentage of vomiting, diarrhoea, pyrexia or hospitalization
between dogs receiving antimicrobials and those without. However,
as assessing antimicrobial prophylaxis was not the primary aim of
the study it is difficult to interpret the significance of this.29 A study
evaluating factors associated with prolonged hospital stay assessed
70 dogs that developed febrile neutropenia following cancer
chemotherapy. About 22% of these dogs had received prophylactic
antimicrobials and there was no significant difference in the length
of hospitalization or survival compared to dogs that had not
received prophylaxis.32
The reduction in cost of treatment and hospitalization rates noted
in human trials would also be key benefits for veterinary chemother-
apy patients if present. Clients may be more willing to proceed with
chemotherapy if there is a lower risk of adverse effects and a reduc-
tion in the overall cost of treatment. With these factors in mind, it is
tempting to prescribe antimicrobials prophylactically in the hope that
they will be protective and reduce adverse effects.
5 | ANTIMICROBIAL RESISTANCE
In spite of the possible benefits of antimicrobial prophylaxis there are
considerable concerns regarding their use, in particular, the develop-
ment of antimicrobial resistance. There are two main factors in the
development and spread of antimicrobial resistance: antimicrobial
selection pressure and clonal dissemination or spread of resistant spe-
cies.36 Administering antimicrobial prophylaxis can exert a selection
pressure within the microbial flora of an individual patient and can
result in the emergence of antimicrobial-resistant strains. There are
increasing reports in the human literature of fluoroquinolone-resistant
organisms isolated from patients receiving chemotherapy prophylaxis.
One literature review reported resistance to standard prophylactic
antimicrobials in 26.8% of pathogens causing infections after chemo-
therapy in the United States.15 Many centres report an increase in the
number of patients colonized by fluoroquinolone-resistant organisms
in rectal cultures obtained after fluoroquinolone-based prophy-
laxis43,44 and bacteria with increased mutation frequency and antimi-
crobial resistance are present in higher levels in the commensal flora
of patients receiving several courses of antimicrobials.45 In addition,
fluoroquinolone administration has been cited as a risk factor for the
progression from intestinal colonization with extended spectrum
beta-lactamase producing Enterobacteriaceae to blood stream
infection, with a fluoroquinolone resistance rate of greater than 50%
among Escherichia coli bloodstream isolates in some cancer
patients.44,46 In one study, levofloxacin administration also tended to
increase the minimum inhibitory concentration for viridans group
streptococci in the bowel and throat microflora of patients with
haematological malignancies.46
Specific veterinary studies assessing resistance in chemotherapy
patients are not available. However, prior antimicrobial use has been
identified as a risk factor for resistance in Staphylococcus pseudointer-
medius ear and skin isolates in dogs.47 Increasing number of antimicro-
bial courses was also associated with increased risk of development of
methicillin-resistant Staphylococcus aureus (MRSA) in a case control
study involving 150 veterinary practices.48 One study in 7 healthy
dogs found that faecal E. coli species exhibited resistance to multiple
antimicrobials after 4 to 7 days of amoxicillin administration.49 Resis-
tant organisms also tended to return to pre-antimicrobial administra-
tion levels and resistance profiles following cessation of antimicrobials
in some studies.44,49
One meta-analysis did not find any significant increase in infec-
tions caused by resistant pathogens in patients receiving prophylactic
antimicrobials compared to placebo.50 In addition, it can be difficult to
determine whether the increasing number of resistant bacteria
isolated from oncology patients are because of patient-specific antimi-
crobial prophylaxis or whether they are a symptom of the general
increase in incidence of resistant nosocomial infections.2 However,
the reality of a global rise in resistant infections is inescapable and
therefore careful consideration must be given to the benefits vs risks
of prophylactic antimicrobial use.2
6 | THE MICROBIOME
Systemically administered antimicrobials have been reported to have
a dramatic impact on the composition and function of the gastrointes-
tinal microbiome, a key factor in increasing gastrointestinal coloniza-
tion by pathogenic and resistant bacteria.51 There is also significant
evidence in humans that disruption of the intestinal microbiome
during chemotherapy because of prophylactic antimicrobials as well
as immunosuppression and mucositis can predispose to infections
with Clostridium difficile.52
Worryingly, there is now increasing evidence that disruption of
the microbiome may reduce the efficacy of chemotherapy treatment.
A study in mouse models of colon carcinoma and melanoma has
revealed that tumour necrosis and immune responses after treatment
with platinum chemotherapy were reduced in mice treated with anti-
microbials prior to therapy.53 In addition, melanoma, sarcoma and
colon cancers failed to respond to CTLA-4 blockade immunotherapy
in antimicrobial-treated mice, and antimicrobials with Gram-positive
spectrum reduced the efficacy of cyclophosphamide when adminis-
tered to mice with lymphoma.54,55 Based on these studies it is sus-
pected that the commensal microbiome (particularly in the small
intestine) is essential for an optimal response to chemotherapy. This is
likely to be because of the effects such as bacterial translocation and
activation of helper T cells, induction of reactive oxygen species and
modulation of cell functions in the tumour microenvironment.51
Other detrimental effects to patient health have been reported
with disruptions to the microbiome including alterations in metabo-
lites and cytokine profiles and inflammatory immune responses. One
study found that alterations in the intestinal microbiome of patients
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receiving fluoroquinolone prophylaxis after haematopoietic stem cell
transplantation were predictive of pulmonary complications such as
lung infiltration.56 A “catch 22” situation has been described in human
medicine where chemotherapy induces mucosal injury and inflamma-
tory response, antimicrobials are given prophylactically at this stage to
try to prevent infection but induce microbial dysbiosis leading to
potential pulmonary complications, reduced responses to chemother-
apy, inflammatory colitis, C. difficile and resistant infections.51
There are several studies indicating that prophylactic antimicro-
bials may have similar effects on microbial diversity and disruption
of the microbiome in dogs. One study reported that administration
of the macrolide antimicrobial tylosin altered microbial composition
and had prolonged effects with changes continuing for over 28 days
after completion of a 14-day antimicrobial course.57 Another study
demonstrated that oral administration of metronidazole markedly
decreased bacterial diversity in the gut microbiome with an
increase in potentially pathogenic bacteria such as Enterococcaceae,
Enterobacteriaceae and Streptococcus.58
7 | PATIENTS AT RISK
With mounting evidence of the disadvantages of antimicrobials, it is
important to try to refine their use in cancer chemotherapy patients.
The National Institute for Health and Care Excellence (NICE) provides
clinical guidelines for the management of neutropenic sepsis in human
patients with cancer treated in the United Kingdom. These guidelines
are based on systematic reviews of the literature but also consider
cost effectiveness. They recommend fluoroquinolone prophylaxis for
adult patients most at risk of developing sepsis. These are patients
with acute leukaemias, stem cell transplants, those on high dose
chemotherapy and those in the first cycle of chemotherapy.36,59
Risk of infection is a key concept on which many human antimicro-
bial prophylaxis guidelines are based.60,61 Many human hospitals use
the multi-national association for supportive care in cancer (MASSC)
index to stratify patients at risk of sepsis and allow them to prescribe
prophylaxis in a more targeted way. This index found that patients were
more likely to have septic complications if they presented with hypo-
tension, respiratory failure, altered mental status, congestive cardiac
failure, arrhythmias, renal failure, were over the age of 60 or had severe
symptoms of their disease or high disease burden.61
In dogs, a case control study by Sorenmo et al investigated risk fac-
tors for development of febrile neutropenia and revealed several similar
risk factors to the human studies.62 Thirty-nine dogs that developed
febrile neutropenia while undergoing standard cancer chemotherapy
protocols for various malignancies were compared to randomly selected
controls that did not develop febrile neutropenia but were receiving
similar chemotherapy protocols. This study found that dogs with lym-
phoma and dogs with lower body weights were significantly more likely
to develop febrile neutropenia than larger dogs or those with solid
tumours. The increased risk in smaller dogs has also been observed in
another study where a significant increase in myelosuppression was
noted in dogs weighing under 14 kg compared to dogs weighing
greater than 14 kg.63 In the study on TMPS prophylaxis, the greatest
benefit of prophylaxis was seen in dogs with lymphoma, supporting the
finding that dogs with lymphoma seem to be more at risk of sepsis.24
Lymphoma was also the most common tumour in cats with febrile neu-
tropenia in one paper.64 The Sorenmo et al study also found that dogs
were more likely to develop febrile neutropenia if they had received
doxorubicin or vincristine, and in the Pierro et al study, cats were at
higher risk if they had received lomustine or vinka alkaloids.64 However,
as these drugs are used most frequently in lymphoma protocols it is dif-
ficult to determine whether they are truly causative agents of the
increased risk or if this finding is due to confounding.62 An additional
finding of the Sorenmo et al study was that 71.8% of dogs were in the
induction phase of their protocol when they developed febrile neutro-
penia, with 48.7% developing it after receiving the chemotherapeutic
drug for the first time.62
In addition, there is now an increasing evidence that certain
breeds of dog, in particular, Collies and herding breeds, are at
increased risk for toxicity, such as neutropenia, from certain cancer
chemotherapeutics. This is because there is a high frequency of a
germline mutation, the ABCB1Delta polymorphism (formerly known
as MDR1) in these breeds. This gene encodes a P-glycoprotein drug
efflux pump that excretes drugs from the cell in normal dogs. In dogs
with a heterozygous or homozygous mutation, there is decreased
excretion of drugs transported by the pump (such as vincristine and
doxorubicin) and thus increased exposure of the patient to drug toxic-
ity.21,65,66 Genetic testing should be considered for dogs of breeds
with a known risk of the mutation prior to initiation of treatment with
drugs transported by the pump.
A second study by Britton et al, from the same institution as the
Sorenmo study assessed factors associated with prolonged hospital
stay in febrile neutropenic dogs receiving chemotherapy. This study
assessed 70 dogs receiving various cancer chemotherapy protocols
for various malignancies. They found that tachycardia on admission,
gastrointestinal signs, decreasing neutrophil count after admission and
documented infection (pneumonia or urinary tract infection) were all
factors associated with a prolonged hospital stay. In addition, hypo-
tension and granulocyte colony stimulating factor (GCSF) use were
significantly associated with death in hospital although the result for
GCSF was suspected to be because of bias.32 Several of these factors
are also present in the MASSC index, in particular, hypotension. Utili-
zation of these risk factors to guide therapy has obvious potential.
8 | TIMING AND DURATION OF
TREATMENT
If prophylactic antimicrobials are indicated, it is important to consider
when they should be administered. In febrile neutropenia cases,
prompt treatment with empirical antimicrobials is recommended by
both veterinary and human texts. British human guidelines recom-
mend starting antimicrobial therapy within 1 hour of documenting
pyrexia and neutropenia.61 However, several studies have not found
any improvement in mortality or overall outcome based on quicker ini-
tial administration of antimicrobials and this is currently under review
in the human literature.67,68 Despite some conflicting evidence on the
exact timing of initial administration of antimicrobials, waiting for
blood or urinary culture results to inform antimicrobial choice is
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contraindicated.12,13,61 A rational empirical choice must therefore be
made in the first instance.12,13,61
In patients that are not septic, antimicrobials may be administered
prophylactically at the time of cancer chemotherapy protocol initia-
tion or on first documentation of a neutropenia. There are no random-
ized control trials investigating a difference between these times of
administration and meta-analysis has not identified a significant differ-
ence between the two groups, so typically they are combined for
analysis in human studies.35 Starting prophylaxis at the time of
chemotherapy protocol initiation is more common in human studies
while administration of antimicrobials on documentation of a neutro-
penia is more common in veterinary patients. This may be because
neutropenia is far more likely to occur with human chemotherapy
protocols so prophylaxis is administered in anticipation.
An additional complicating factor in deciding when to administer
antimicrobials comes in defining a significant neutropenia. As already
discussed, an ANC of below 0.5 x 109/L is considered high risk for
infection.16 However, the “cut off” ANC at which to start antimicrobial
prophylaxis seems to vary widely among institutions. Human guidelines
in the United States recommend starting antimicrobial prophylaxis only
in patients with an ANC of less than 0.1 x 109/L for longer than
7 days.69 Other studies and British guidelines recommend initiation of
prophylaxis for suspected neutropenia of less than 0.5 x 109/L.33,61
In veterinary patients, the ANC cut off tends to be higher than in
people and most veterinary texts recommend antimicrobials for any
ANC lower than 1.0 x 109/L, although this is an empirical value.12,13,21
The reported reasons for a higher cut off are multiple and include a
less predictable neutrophil nadir and lower tolerance of adverse
effects in pets by clinicians and owners. For most chemotherapy
drugs, the neutrophil nadir is at 5 to 7 days post-administration and
typically CBC is performed 1 week post-chemotherapy administration
to assess the ANC. This blood sample is very much a “snapshot in
time” and does not reflect whether the animal's ANC is rising or falling
on that particular day.13 In addition, some cancer chemotherapy drugs
such as lomustine or carboplatin, have been documented to have a
prolonged or late neutrophil nadir.70,71 As serial blood tests are rarely
a viable option, because of patient compliance and costs, if a border-
line low ANC is documented many clinicians will err on the side of
caution and prescribe prophylactic antimicrobials. In a survey of veter-
inarians attending the 2009 Veterinary Cancer Society Annual Confer-
ence, 9% of vets started antimicrobial prophylaxis for any neutrophil
count lower than the laboratory reference range and 29% of vets
started antimicrobial prophylaxis for any ANC below 1.5 x 109/L in
dogs with lymphoma.72 This suggests that a concerning number of cli-
nicians are prescribing antimicrobials even more frequently than sug-
gested in current veterinary texts. The ANC cut off for antimicrobial
prophylaxis used at the authors' institution is 0.75 x 109/L with recent
data suggesting that this may be reasonable for clinical use.73
The length of antimicrobial administration also varies widely
between centres and protocols, with mean duration of antimicrobial
administration ranging from 10 to 151 days in one recent human meta-
analysis.35 Typically, duration of prophylactic antimicrobials is depen-
dent on the time point at which they were initiated. For instance, in
studies where antimicrobials are administered because a neutropenia is
expected that they are administered for the length of the anticipated
neutropenia (typically around 7 days). One study found that 40% of
febrile neutropenic episodes occurred outside the expected period of
neutropenia (the period of prophylaxis in this study) suggesting that
timing based on the anticipated neutropenia may not be optimal.33
Other studies recommend antimicrobial administration for the entire
time that the patient is receiving cancer chemotherapy. Most veterinary
texts advise a 3 to 7-day course of antimicrobials on documentation of
a neutropenia, although this is not evidence based.12,13,21 An alternative
approach is to administer prophylactic antimicrobials until the ANC has
increased back to above the original cut off value used to initiate the
therapy. This is an approach adopted by our institution and in several
human studies and seems an appropriate approach as long as there is
no documented infection.35
There is limited data comparing antimicrobial courses of 2 to 3 vs
7 days. However, increasing data comparing longer vs shorter antimi-
crobial courses is available. A human systematic review found that
mechanically ventilated patients with hospital-acquired pneumonia
receiving a 7-day course of antimicrobials had the same clinical
outcomes as similar patients receiving a 10 to 15-day course, with
some evidence that those receiving a 7-day course were less likely to
develop multi-resistant infections.74 However, neutropenic patients
were excluded from several of the studies in this review.74 The find-
ings are similar to those of a retrospective, multi-centre, cohort study
which found that human patients with Enterobacteriaceae bacterae-
mia treated with a short antimicrobial course (median 8 days) had the
same mortality and infection recurrence rates as those treated with a
longer antimicrobial course (median 15 days).75 Around 34% of
patients in the study were immunocompromised, for a variety of rea-
sons including chemotherapy, split evenly between the short and long
course groups.75 Fewer multi-drug resistant infections were described
with the shorter antibiotic course in this study.75 A recent veterinary,
prospective, observational study in 47 dogs with uncomplicated
pneumonia did not find any significant difference between dogs trea-
ted with a short course of antimicrobials (<14 days) compared to
those treated with a longer course (>14 days) in radiographic resolu-
tion or relapse rate. However, these data can only be considered as
preliminary as the dogs were not randomized and only 3 had
confirmed bacterial pneumonia.76 Dogs in this study were excluded if
they had received chemotherapy.76 While further studies are needed
in patients that have received chemotherapy, withdrawing prophylaxis
on resolution of clinical signs and severe neutropenia appears to be a
more appropriate choice than an empirical 7-day course, as the dogma
of “completing the course” is increasingly challenged.77 This is
supported in the ACVIM consensus on antimicrobial use in animals
where they advise that antimicrobials should never be continued once
there is clinical and microbiological evidence that an infection has
been eliminated.78
In addition to the appropriate length of treatment consideration
should also be paid to the pharmacokinetics and pharmacodynamics
of the antimicrobial used with particular care taken to consider the
dose, dosing interval and site of desired action of the drug.79 It is vital
to use antimicrobials at an appropriately high dose as there is increas-
ing evidence that subtherapuetic doses of antimicrobials may increase
bacterial resistance.78
BISSON ET AL. 5
9 | CHOICE OF ANTIMICROBIAL
An additional important factor to consider is the choice of drug.
In most infections in cancer chemotherapy patients, the source of
septicaemia is bacterial translocation from the patient's own gastroin-
testinal tract. Other sources or sites of infection such as the urinary
tract, respiratory tract or skin are also possible.
For patients that are febrile neutropenic, veterinary texts advise
broad spectrum intravenous coverage for both Gram-positive and
Gram-negative organisms and anaerobic and aerobic bacteria. This
would involve a combination of drugs such as a penicillin and amino-
glycoside combination or a cephalosporin and fluoroquinolone.12
Significantly, human guidelines are moving away from this type of
recommendation, with a clear shift away from extensive antimicrobial
cover even in patients with suspected sepsis.61 Use of a single antimi-
crobial is recommended with no addition of aminoglycosides unless
there is a patient-specific indication such as a confirmed aminoglyco-
side responsive infection.61 Meta-analysis of several human random-
ized control trials has found that oral antimicrobials (quinolones alone
or combined with another antimicrobial) were as effective in prevent-
ing mortality and treating sepsis as intravenous antimicrobials in
febrile neutropenic patients considered to be “low risk” of septic
complications (as decided by the MASCC index).80
In a prophylactic setting, it is therefore even more important not
to prescribe extensive and unnecessary antimicrobial coverage. In
human oncology, the most frequently used antimicrobial for prophy-
laxis is levofloxacin, a second generation fluoroquinolone. Quinolones
are generally favoured because of their broad spectrum of action, high
concentration in faeces and minimal side effects. They also have very
little activity against anaerobic bacteria, this spares the anaerobic
gastrointestinal flora and can help to prevent overgrowth of patho-
genic bacteria.35 TMPS have similar broad spectrum and anaerobe
sparing qualities, although they have been found to cause more
adverse effects than quinolones including myelosuppression and
C. difficile colitis.60 Meta-analysis has not revealed any significant
difference between quinolones and TMPS in mortality, febrile
episodes or bacteraemia, yet it did find that the occurrence of Gram-
negative infections and adverse effects were less in the quinolone
group as opposed to the TMPS group.35
Some concerns have been raised that quinolones may not provide
adequate cover for Gram-positive organisms such as viridans strepto-
cocci and coagulase negative staphylococci and the addition of Gram-
positive cover with antimicrobials such as rifampin or amoxicillin has
been trialled. Meta-analysis of these trials reveals that while there
was a decrease in the number of Gram-positive bacteraemia episodes
there was no significant difference in mortality and a significant
increase in side effects in the patients receiving additional cover com-
pared to quinolones alone.35,81 An additional study found that
patients receiving cyclophosphamide for chronic lymphocytic leukae-
mia who received antimicrobials with a Gram-positive spectrum had
significantly reduced progression free and overall survival times com-
pared to those receiving primarily Gram-negative spectrum antimicro-
bials or no antimicrobials at all. This finding is suspected to be related
to alterations in the microbiome as discussed above.82
For antimicrobial prophylaxis in afebrile neutropenic animals veteri-
nary texts advise oral antimicrobials similar to those used in humans,
such as enrofloxacin or TMPS.12,13,21 The only trial assessing prophylac-
tic antimicrobials in dogs receiving cancer chemotherapy used TMPS. In
this study, there was no obvious toxicity attributed to TMPS and as dis-
cussed above there was reduced morbidity in dogs that received it com-
pared to placebo receiving controls.24 TMPS also have the advantage of
not being considered a critically important antimicrobial class for human
use; but they are associated with a number of adverse effects in dogs
including blood dyscrasias, keratoconjunctivitis sicca, hypothyroidism,
hyperkalaemia, cholestasis, acute hepatic necrosis and skin disease.83
This association has made them a less popular clinical choice. There is
no specific literature regarding prophylactic quinolones in veterinary
medicine. However, they have a similar spectrum of action to TMPS
and generally seem to be better tolerated in dogs; although adverse
effects can still occur including cartilage damage in young, growing ani-
mals, retinal toxicity in cats and reduced seizure thresholds.84
Yet unlike TMPS, fluoroquinolones are listed by the World Health
Organization as critically important for human medicine and should
therefore be safeguarded with any prophylactic use discouraged.85
Also, quinolones are notorious in driving evolution of resistant bacte-
ria and have been suggested to be a crucial factor in the evolution of
hospital MRSA.2 The NICE guidelines recommend that cancer centres
in which patients are receiving fluoroquinolones for antimicrobial pro-
phylaxis should monitor rates of antimicrobial resistance.61 In addi-
tion, 2010 guidelines from the Infectious Diseases Society of America
do not recommend routine use of fluoroquinolone prophylaxis in low
risk (according to MASCC index) patients because of the low likeli-
hood of sepsis in this group.60 In veterinary patients the use of quino-
lones, particularly in a prophylactic setting has to be considered very
carefully. A recent survey of Belgian general practice vets found that
fluoroquinolones were the second most frequently prescribed antimi-
crobial after amoxicillin-clavulanic acid in dogs, in a recent UK study
they were the fifth most frequently prescribed and studies in Italy and
New Zealand also describe frequent use.9–11,86 All of these studies
commented that there was a tendency for overuse of fluoroquino-
lones, particularly for treatment of common diseases where broad
spectrum cover is not required.9–11,86 There is an obvious disparity
between fluoroquinolone usage guidelines and clinical use, and the
responsibility for reducing their use and using them only for appropri-
ate clinical indications lies with veterinary clinicians.9
10 | GRANULOCYTE COLONY
STIMULATING FACTOR
A possible alternative to prophylactic antimicrobials for neutropenia is
the administration of GCSF. GCSF is a haematopoietic growth factor
that promotes the proliferation and maturation of neutrophil precur-
sors in the bone marrow thus increasing the neutrophil count.87 There
are several synthetic, injectable versions available such as filgrastim
and pegfilgrastim. In human patients, prophylactic administration of
these drugs has been shown to reduce the duration of grade 3 or
4 neutropenias and decrease the incidence of febrile neutropenias.23
Some studies have suggested that use of GCSFs may decrease
6 BISSON ET AL.
hospitalizations and reduce the need for intravenous antimicrobials.88
They are generally well tolerated in humans; the main side effect is
bone pain although other less common adverse effects such as myal-
gia, psoriasis, vasculitis, pain on injection and headache have been
reported.89 This appears promising, yet their use in human oncology
remains controversial, partly because several studies have been
unable to demonstrate a reduction in mortality for patients receiving
GCSFs.88,89 These drugs are also expensive and economic analysis has
suggested that administration of GCSFs in human chemotherapy
patients is highly unlikely to be cost effective.61,90 The NICE guide-
lines for UK practice recommend against offering GCSF for most
patients unless they are undergoing a chemotherapy protocol with
particularly high dose intensity.61 US guidelines only recommend
primary prophylaxis with GCSF for patients on a high risk chemother-
apy protocol (one with a febrile neutropenia risk of greater than
20%).23 Meta-analysis of two randomized control trials comparing the
use of GCSF to prophylactic antimicrobials was unable to draw any
useful conclusions to inform clinical practice because of low patient
numbers, although there was no obvious difference between the
2 groups in mortality or febrile neutropenias.88
There is very limited evidence on the use of GCSF in dogs; canine
recombinant GCSF is not readily available and is extremely expensive,
human alternatives are available but are also costly.21 With human
GCSF there is a risk of cross species antibody production which may
neutralize not only the human GCSF but also the endogenous canine
GCSF and has been reported to lead to severe neutropenias.91 One
study found that canine GCSF did accelerate the recovery and
decrease the severity of neutropenias in dogs treated with cyclophos-
phamide.91 Since the study only looked at 6 healthy research beagles
it cannot be used to guide treatment in canine cancer patients of vary-
ing breeds. Most veterinary texts therefore do not currently advise
the use of GCSFs in veterinary patients except in cases of very severe
neutropenia that is expected to be prolonged or if a known chemo-
therapy overdose has occured.12,21,92
11 | RECOMMENDATIONS
Because of the paucity of a veterinary-specific evidence base in this
area, recommendations must be formulated relying heavily on extrap-
olation from human guidelines with the addition of minimal and
TABLE 1 Recommendations for prophylactic antimicrobial use in clinically well dogs undergoing cancer chemotherapy
Prophylactic antimicrobial use Choice of antimicrobial Duration of treatment
Use indicated
Neutrophil count: <0.75 × 109/L Anaerobe sparing, broad-spectrum antimicrobial If no infection is documented:
Do not prescribe additional Gram-positive cover Measure CBC 3 days after antimicrobials are started
Stop antimicrobials when the neutrophil count is >0.75 × 109/L
Use should be considered
Neutrophil count: >0.75 × 109/L and <1 × 109/L and one or
more of the risk factors below:
• Haematological malignancies
• Concomitant disease
• Collie or herding breed that has tested positive for
the ABCB-1delta mutation and is being treated with
doxorubicin or a vinca alkaloid
• Weight less than 14 kg
Anaerobe sparing, broad-spectrum
antimicrobial
If no infection is documented:
Do not prescribe additional Gram-positive
cover
Measure CBC 3 days after
antimicrobials are started
Stop antimicrobials when the
neutrophil count is >1 × 109/L
Do not use
Neutrophil count: >1 × 109/L
Neutrophil count: >0.75 × 109/L and no risk factors
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anecdotal veterinary evidence. Multi-centre veterinary trials are
required to generate the evidence on which to build veterinary-
specific guidance. With the current climate of increasing antimicrobial
resistance and the drive to reduce antimicrobial use, particularly
within the veterinary sector it is vital that centres begin to investigate
antimicrobial prophylaxis in more detail. On this basis we have
constructed the following guidance as shown in Table 1.
The evidence has been ranked using the revised evidence pyra-
mid for veterinary clinical resources suggested at a recent evidence-
based veterinary medicine association (EBVMA) symposium by Fricke
(Figure 1).93
ACKNOWLEDGEMENTS
The authors thank the members of the Oncology Service of the R(D)
SVS who contributed to some of the anecdotal data and expert
opinion discussed within this review.
Conflict of interest
The authors declare no conflict of interest in this research and no
external funding was sought or obtained.
ORCID
J. L. Bisson http://orcid.org/0000-0001-5337-1807
REFERENCES
1. Smith R, Coast J. The true cost of antimicrobial resistance. BMJ. 2013;
346:f1493.
2. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the
need for global solutions. Lancet Infect Dis. 2013;13(12):1057-1098.
3. Guardabassi L, Prescott JF. Antimicrobial stewardship in small animal
veterinary practice from theory to practice. Vet Clin North Am Small
Anim Pract. 2015;45(2):361-376, vii.
4. American Veterinary Medical Association. Antimicrobial Stewardship
Definition and Core Principles. https://www.avma.org/KB/Policies/
Pages/Antimicrobial-Stewardship-Definition-and-Core-Principles.
aspx. Accessed March 22, 2018.
5. Teale CJ, Moulin G. Prudent use guidelines: a review of existing veteri-
nary guidelines. Rev Sci Tech. 2012;31(1):343-354.
6. Knights CB, Mateus A, Baines SJ. Current British veterinary attitudes
to the use of perioperative antimicrobials in small animal surgery. Vet
Rec. 2012;170(25):646.
7. British Small Animal Veterinary Association. Reducing prophylaxis.
https://www.bsava.com/Resources/Veterinary-resources/PROTECT/
Reducing-Prophylaxis. Accessed January 2, 2018.
8. Hardefeldt LY, Browning GF, Thursky K, et al. Antimicrobials used for
surgical prophylaxis by companion animal veterinarians in Australia.
Vet Microbiol. 2017;203:301-307.
9. Van Cleven A, Sarrazin S, de Rooster H, Paepe D, Van der Meeren S,
Dewulf J. Antimicrobial prescribing behaviour in dogs and cats by Bel-
gian veterinarians. Vet Rec. 2017;182:324.
10. Pleydell EJ, Souphavanh K, Hill KE, French NP, Prattley DJ. Descrip-
tive epidemiological study of the use of antimicrobial drugs by
companion animal veterinarians in New Zealand. N Z Vet J. 2012;
60(2):115-122.
11. Buckland EL, O'Neill D, Summers J, et al. Characterisation of antimi-
crobial usage in cats and dogs attending UK primary care companion
animal veterinary practices. Vet Rec. 2016;179(19):489.
FIGURE 1 A revised evidence pyramid for
veterinary clinical resources. Based on the
recent evidence-based veterinary medicine
association (EBVMA) symposium by
Fricke93
8 BISSON ET AL.
12. Thamm DH, Vail DM. Aftershocks of cancer chemotherapy: managing
adverse effects. J Am Anim Hosp Assoc. 2007;43(1):1-7.
13. Boudreaux B. Antimicrobial use in the veterinary cancer patient. Vet
Clin North Am Small Anim Pract. 2014;44(5):883-891.
14. Liss B, Cornely OA. Burden and benefit of antibiotic prophylaxis in
cancer chemotherapy. Lancet Infect Dis. 2016;16(6):640.
15. Teillant A, Gandra S, Barter D, Morgan DJ, Laxminarayan R. Potential
burden of antibiotic resistance on surgery and cancer chemotherapy
antibiotic prophylaxis in the USA: a literature review and modelling
study. Lancet Infect Dis. 2015;15(12):1429-1437.
16. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relation-
ships between circulating leukocytes and infection in patients with
acute leukemia. Ann Intern Med. 1966;64(2):328-340.
17. Rolston KV. Infections in cancer patients with solid tumors: a review.
Infect Dis Ther. 2017;6(1):69-83.
18. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent
bacterial infection in patients with cancer and neutropenia. N Engl J
Med. 2005;353(10):977-987.
19. Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence,
treatment, and consequences of chemotherapy-induced febrile
neutropenia in the inpatient and outpatient settings. J Oncol Pharm
Pract. 2014;20(3):190-198.
20. Veterinary Cooperative Oncology Group. Veterinary cooperative
oncology group-common terminology criteria for adverse events
(VCOG-CTCAE) following chemotherapy or biological antineoplastic
therapy in dogs and cats v1.1. Vet Comp Oncol. 2016;14(4):417-446.
21. Vail DM. Supporting the veterinary cancer patient on chemotherapy:
neutropenia and gastrointestinal toxicity. Top Companion Anim Med.
2009;24(3):122-129.
22. Abrams-Ogg ACG, Kruth SA. Management of Infections Associated
with Neutropenia in the Dog and Cat. In: Giguere S, Prescott JF,
Dowling JM, eds. Antimicrobial Therapy in Veterinary Medicine. Hobo-
ken, NJ, USA: John Wiley & Sons Inc.; 2013.
23. Jolis L, Carabantes F, Pernas S, et al. Incidence of chemotherapy-induced
neutropenia and current practice of prophylaxis with granulocyte
colony-stimulating factors in cancer patients in Spain: a prospective,
observational study. Eur J Cancer Care. 2013;22(4):513-521.
24. Chretin JD, Rassnick KM, Shaw NA, et al. Prophylactic
trimethoprim-sulfadiazine during chemotherapy in dogs with
lymphoma and osteosarcoma: a double-blind, placebo-controlled
study. J Vet Intern Med. 2007;21(1):141-148.
25. MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM. Does
L-asparaginase influence efficacy or toxicity when added to a standard
CHOP protocol for dogs with lymphoma? J Vet Intern Med. 2005;
19(5):732-736.
26. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a
6-month chemotherapy protocol with no maintenance therapy for
dogs with lymphoma. J Vet Intern Med. 2002;16(6):704-709.
27. Sharma A, Lokeshwar N. Febrile neutropenia in haematological malig-
nancies. J Postgrad Med. 2005;51(suppl 1):S42-S48.
28. Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia
among patients with cancer receiving chemotherapy: a systematic
review. Crit Rev Oncol Hematol. 2014;90(3):190-199.
29. Marrington AM, Killick DR, Grant IA, Blackwood L. Toxicity associated
with epirubicin treatments in a large case series of dogs. Vet Comp
Oncol. 2012;10(2):113-123.
30. Ahaus EA, Couto CG, Valerius KD. Hematological toxicity of
doxorubicin-containing protocols in dogs with spontaneously occur-
ring malignant tumors. J Am Anim Hosp Assoc. 2000;36(5):422-426.
31. Northrup NC, Rassnick KM, Snyder LA, et al. Neutropenia associated
with vincristine and L-asparaginase induction chemotherapy for canine
lymphoma. J Vet Intern Med. 2002;16(5):570-575.
32. Britton BM, Kelleher ME, Gregor TP, Sorenmo KU. Evaluation of fac-
tors associated with prolonged hospital stay and outcome of febrile
neutropenic patients receiving chemotherapy: 70 cases (1997-2010).
Vet Comp Oncol. 2014;12(4):266-276.
33. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after
chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;
353(10):988-998.
34. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic
prophylaxis reduces mortality in neutropenic patients. Ann Intern Med.
2005;142(12, pt 1):979-995.
35. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacte-
rial infections in afebrile neutropenic patients following chemother-
apy. Cochrane Database Syst Rev. 2012;1:CD004386.
36. Lo N, Cullen M. Antibiotic prophylaxis in chemotherapy-induced neu-
tropenia: time to reconsider. Hematol Oncol. 2006;24(3):120-125.
37. Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M. Factors
associated with early termination of CHOP therapy and the impact on
survival among patients with chemosensitive intermediate-grade
non-Hodgkin's lymphoma. Cancer Control. 2003;10(5):396-403.
38. Hammer AS, Couto CG, Filppi J, Getzy D, Shank K. Efficacy and toxic-
ity of VAC chemotherapy (vincristine, doxorubicin, and cyclophospha-
mide) in dogs with hemangiosarcoma. J Vet Intern Med. 1991;5(3):
160-166.
39. Rassnick KM, Bailey DB, Russell DS, et al. A phase II study to evaluate
the toxicity and efficacy of alternating CCNU and high-dose vinblas-
tine and prednisone (CVP) for treatment of dogs with high-grade, met-
astatic or nonresectable mast cell tumours. Vet Comp Oncol. 2010;
8(2):138-152.
40. Bailey DB, Rassnick KM, Kristal O, Chretin JD, Balkman CE. Phase I
dose escalation of single-agent vinblastine in dogs. J Vet Intern Med.
2008;22(6):1397-1402.
41. Flory AB, Rassnick KM, Al-Sarraf R, et al. Combination of CCNU and
DTIC chemotherapy for treatment of resistant lymphoma in dogs. J
Vet Intern Med. 2008;22(1):164-171.
42. Rassnick KM, Bailey DB, Flory AB, et al. Efficacy of vinblastine for
treatment of canine mast cell tumors. J Vet Intern Med. 2008;22(6):
1390-1396.
43. Roberts MJ, Williamson DA, Hadway P, Doi SA, Gardiner RA,
Paterson DL. Baseline prevalence of antimicrobial resistance and sub-
sequent infection following prostate biopsy using empirical or altered
prophylaxis: a bias-adjusted meta-analysis. Int J Antimicrob Agents.
2014;43(4):301-309.
44. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance
of Escherichia coli at a cancer center: epidemiologic evolution and
effects of discontinuing prophylactic fluoroquinolone use in neutrope-
nic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24(2):
111-118.
45. Gustafsson I, Sjolund M, Torell E, et al. Bacteria with increased muta-
tion frequency and antibiotic resistance are enriched in the commen-
sal flora of patients with high antibiotic usage. J Antimicrob Chemother.
2003;52(4):645-650.
46. Timmers GJ, Dijstelbloem Y, Simoons-Smit AM, et al. Pharmacokinetics
and effects on bowel and throat microflora of oral levofloxacin as
antibacterial prophylaxis in neutropenic patients with haematological
malignancies. Bone Marrow Transplant. 2004;33(8):847-853.
47. Zur G, Gurevich B, Elad D. Prior antimicrobial use as a risk factor for
resistance in selected Staphylococcus pseudintermedius isolates from
the skin and ears of dogs. Vet Dermatol. 2016;27(6):468-474.
48. Soares Magalhaes RJ, Loeffler A, Lindsay J, et al. Risk factors for
methicillin-resistant Staphylococcus aureus (MRSA) infection in dogs
and cats: a case-control study. Vet Res. 2010;41(5):55.
49. Gronvold AM, L'Abee-Lund TM, Sorum H, Skancke E, Yannarell AC,
Mackie RI. Changes in fecal microbiota of healthy dogs administered
amoxicillin. FEMS Microbiol Ecol. 2010;71(2):313-326.
50. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone
prophylaxis in afebrile neutropenic patients on microbial resistance:
systematic review and meta-analysis. J Antimicrob Chemother. 2007;
59(1):5-22.
51. Galloway-Pena JR, Jenq RR, Shelburne SA. Can consideration of the
microbiome improve antimicrobial utilization and treatment outcomes
in the oncology patient? Clin Cancer Res. 2017;23(13):3263-3268.
52. Taur Y, Pamer EG. The intestinal microbiota and susceptibility to
infection in immunocompromised patients. Curr Opin Infect Dis. 2013;
26(4):332-337.
53. Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control
cancer response to therapy by modulating the tumor microenviron-
ment. Science. 2013;342(6161):967-970.
BISSON ET AL. 9
54. Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by
CTLA-4 blockade relies on the gut microbiota. Science. 2015;
350(6264):1079-1084.
55. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modu-
lates the anticancer immune effects of cyclophosphamide. Science.
2013;342(6161):971-976.
56. Harris B, Morjaria SM, Littmann ER, et al. Gut microbiota predict pul-
monary infiltrates after allogeneic hematopoietic cell transplantation.
Am J Respir Crit Care Med. 2016;194(4):450-463.
57. Suchodolski JS, Dowd SE, Westermarck E, et al. The effect of the
macrolide antibiotic tylosin on microbial diversity in the canine small
intestine as demonstrated by massive parallel 16S rRNA gene
sequencing. BMC Microbiol. 2009;9:210.
58. Igarashi H, Maeda S, Ohno K, Horigome A, Odamaki T, Tsujimoto H.
Effect of oral administration of metronidazole or prednisolone on fecal
microbiota in dogs. PLoS One. 2014;9(9):e107909.
59. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational
Association for Supportive Care in cancer risk index: a multinational
scoring system for identifying low-risk febrile neutropenic cancer
patients. J Clin Oncol. 2000;18(16):3038-3051.
60. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline
for the use of antimicrobial agents in neutropenic patients with can-
cer: 2010 update by the Infectious Diseases Society of America. Clin
Infect Dis. 2011;52(4):e56-e93.
61. Phillips R, Hancock B, Graham J, Bromham N, Jin H, Berendse S.
Prevention and management of neutropenic sepsis in
patients with cancer: summary of NICE guidance. BMJ. 2012;345:
e5368.
62. Sorenmo KU, Harwood LP, King LG, Drobatz KJ. Case-control study
to evaluate risk factors for the development of sepsis (neutropenia
and fever) in dogs receiving chemotherapy. J Am Vet Med Assoc. 2010;
236(6):650-656.
63. Page RL, Macy DW, Thrall DE, et al. Unexpected toxicity associated
with use of body surface area for dosing melphalan in the dog. Cancer
Res. 1988;48(2):288-290.
64. Pierro J, Krick E, Flory A, et al. Febrile neutropenia in cats treated with
chemotherapy. Vet Comp Oncol. 2017;15(2):550-556.
65. Mealey KL, Fidel J, Gay JM, Impellizeri JA, Clifford CA, Bergman PJ.
ABCB1-1Delta polymorphism can predict hematologic toxicity in
dogs treated with vincristine. J Vet Intern Med. 2008;22(4):
996-1000.
66. Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Delta (mul-
tidrug sensitivity) polymorphism among dogs undergoing ABCB1 gen-
otyping. J Am Vet Med Assoc. 2008;233(6):921-924.
67. Sterling SA, Miller WR, Pryor J, Puskarich MA, Jones AE. The impact
of timing of antibiotics on outcomes in severe sepsis and septic shock:
a systematic review and meta-analysis. Crit Care Med. 2015;43(9):
1907-1915.
68. Ko BS, Ahn S, Lee YS, Kim WY, Lim KS, Lee JL. Impact of time to anti-
biotics on outcomes of chemotherapy-induced febrile neutropenia.
Support Care Cancer. 2015;23(9):2799-2804.
69. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and
outpatient management of fever and neutropenia in adults treated for
malignancy: American Society of Clinical Oncology clinical practice
guideline. J Clin Oncol. 2013;31(6):794-810.
70. Page RL, McEntee MC, George SL, et al. Pharmacokinetic and phase I
evaluation of carboplatin in dogs. J Vet Intern Med. 1993;7(4):
235-240.
71. Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the
treatment of resistant lymphoma in dogs. J Vet Intern Med. 1999;
13(5):395-398.
72. Regan RC, Kaplan MS, Bailey DB. Diagnostic evaluation and treatment
recommendations for dogs with substage—a high-grade multicentric
lymphoma: results of a survey of veterinarians. Vet Comp Oncol. 2013;
11(4):287-295.
73. Fournier Q, Serra JC, Handel I, Lawrence J. Impact of pretreatment
neutrophil count on chemotherapy administration and toxicity in dogs
with lymphoma treated with CHOP chemotherapy. J Vet Intern Med.
2017;32(1):384-393.
74. Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus
prolonged-course antibiotic therapy for hospital-acquired pneumonia
in critically ill adults. Cochrane Database Syst Rev. 2015;(8):CD007577.
https://doi.org/10.1002/14651858.CD007577.pub3.
75. Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Comparing the out-
comes of adults with Enterobacteriaceae Bacteremia receiving
short-course versus prolonged-course antibiotic therapy in a multicen-
ter, propensity score-matched cohort. Clin Infect Dis. 2017;66:172-177.
76. Wayne A, Davis M, Sinnott VB, Bracker K. Outcomes in dogs with
uncomplicated, presumptive bacterial pneumonia treated with short
or long course antibiotics. Can Vet J. 2017;58(6):610-613.
77. Llewelyn MJ, Fitzpatrick JM, Darwin E, et al. The antibiotic course has
had its day. BMJ. 2017;358:j3418.
78. Weese JS, Giguere S, Guardabassi L, et al. ACVIM consensus state-
ment on therapeutic antimicrobial use in animals and antimicrobial
resistance. J Vet Intern Med. 2015;29(2):487-498.
79. Onufrak NJ, Forrest A, Gonzalez D. Pharmacokinetic and pharmacody-
namic principles of anti-infective dosing. Clin Ther. 2016;38(9):1930-1947.
80. Vidal L, Ben Dor I, Paul M, et al. Oral versus intravenous antibiotic
treatment for febrile neutropenia in cancer patients. Cochrane Data-
base Syst Rev. 2013;(10):CD003992. https://doi.org/10.1002/
14651858.CD003992.pub3.
81. Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C.
Reappraisal with meta-analysis of the addition of Gram-positive pro-
phylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol.
2003;21(22):4127-4137.
82. Pflug N, Kluth S, Vehreschild JJ, et al. Efficacy of antineoplastic treat-
ment is associated with the use of antibiotics that modulate intestinal
microbiota. Oncoimmunology. 2016;5(6):e1150399.
83. Trepanier LA. Idiosyncratic toxicity associated with potentiated sul-
fonamides in the dog. J Vet Pharmacol Ther. 2004;27(3):129-138.
84. Spohr ASB, Wiinberg B, Houser G, Willesen J, Jessen LR,
Guardabassi L, Schjaerff M, Eriksen T, Jensen V. Antibiotic use guide-
lines for companion animal practice. Danish Small Animal Veterinary
Association 2009.
85. World Health Organization. Critically Important Antimicrobials for
Human Medicine, 5th revision, 2016.
86. Escher M, Vanni M, Intorre L, Caprioli A, Tognetti R, Scavia G. Use of
antimicrobials in companion animal practice: a retrospective study in a
veterinary teaching hospital in Italy. J Antimicrob Chemother. 2011;
66(4):920-927.
87. Xu S, Hoglund M, Hakansson L, Venge P. Granulocyte
colony-stimulating factor (G-CSF) induces the production of cytokines
in vivo. Br J Haematol. 2000;108(4):848-853.
88. Skoetz N, Bohlius J, Engert A, Monsef I, Blank O, Vehreschild JJ.
Prophylactic antibiotics or G(M)-CSF for the prevention of infections
and improvement of survival in cancer patients receiving myelotoxic
chemotherapy. Cochrane Database Syst Rev. 2015;(12):CD007107.
https://doi.org/10.1002/14651858.CD007107.pub3.
89. Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating
factors to prevent adverse effects in the treatment of malignant
lymphoma. Cochrane Database Syst Rev. 2004;(1):CD003189.
90. Barnes G, Pathak A, Schwartzberg L. Pharmacoeconomics of granulocyte
colony-stimulating factor: a critical review.Adv Ther. 2014;31(7):683-695.
91. Yamamoto A, Fujino M, Tsuchiya T, Iwata A. Recombinant canine
granulocyte colony-stimulating factor accelerates recovery from
cyclophosphamide-induced neutropenia in dogs. Vet Immunol Immuno-
pathol. 2011;142(3–4):271-275.
92. Finlay JR, Wyatt K, North C. Recovery from cyclophosphamide over-
dose in a dog. J Am Anim Hosp Assoc. 2017;53(4):230-235.
93. Fricke S. Evidence-based veterinary medicine association. A revised evi-
dence pyramid for veterinary clinical resources. Published November 11,
2014. https://ebvma.org/a-revised-evidence-pyramid-for-veterinary-
clinical-resources/. Accessed March 24, 2018.
How to cite this article: Bisson JL, Argyle DJ, Argyle SA. Anti-
biotic prophylaxis in veterinary cancer chemotherapy: A
review and recommendations. Vet Comp Oncol. 2018;1–10.
https://doi.org/10.1111/vco.12406
10 BISSON ET AL.
